Wolfgang Hueber

6.7k total citations · 2 hit papers
46 papers, 3.9k citations indexed

About

Wolfgang Hueber is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Physiology. According to data from OpenAlex, Wolfgang Hueber has authored 46 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 20 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Physiology. Recurrent topics in Wolfgang Hueber's work include Monoclonal and Polyclonal Antibodies Research (20 papers), Systemic Lupus Erythematosus Research (17 papers) and Rheumatoid Arthritis Research and Therapies (13 papers). Wolfgang Hueber is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (20 papers), Systemic Lupus Erythematosus Research (17 papers) and Rheumatoid Arthritis Research and Therapies (13 papers). Wolfgang Hueber collaborates with scholars based in United States, Switzerland and Germany. Wolfgang Hueber's co-authors include William H. Robinson, Paul J. Utz, Arthur P. Bertolino, Gerard Bruin, Mark C. Genovese, Steve Lewitzky, Simon Travis, Marek Karczewski, Michael Yao and Brian G. Feagan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Wolfgang Hueber

45 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

2012 1.2k citations Wolfgang Hueber, Bruce E. Sands et al. Gut profile →
Autoantigen microarrays for multiplex characterization of autoantibody responses

2002 529 citations William H. Robinson, Wolfgang Hueber et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wolfgang Hueber United States	23	1.9k	1.5k	992	980	552	46	3.9k
Rosa Sorrentino Italy	31	2.1k 1.1×	1.1k 0.7×	626 0.6×	422 0.4×	284 0.5×	110	3.6k
William F. C. Rigby United States	39	1.5k 0.8×	2.0k 1.3×	1.9k 2.0×	449 0.5×	253 0.5×	102	5.2k
Emily C. Baechler United States	24	2.8k 1.5×	2.6k 1.7×	1.0k 1.1×	639 0.7×	371 0.7×	34	4.6k
Hans Ulrich Scherer Netherlands	34	2.1k 1.1×	2.0k 1.3×	1.5k 1.5×	1.5k 1.5×	163 0.3×	103	4.5k
Joyce Rauch Canada	38	2.7k 1.4×	3.2k 2.1×	957 1.0×	2.0k 2.1×	552 1.0×	122	6.0k
Wolfgang Dummer United States	29	2.7k 1.4×	499 0.3×	451 0.5×	355 0.4×	209 0.4×	56	3.9k
Hervé Watier France	32	2.2k 1.1×	445 0.3×	1.2k 1.2×	2.2k 2.2×	854 1.5×	112	5.4k
Stephen Adelstein Australia	27	2.4k 1.3×	417 0.3×	413 0.4×	629 0.6×	340 0.6×	75	3.5k
Rufus W. Burlingame United States	26	1.1k 0.6×	1.1k 0.7×	1.1k 1.1×	597 0.6×	225 0.4×	58	2.8k
Federico Perosa Italy	25	1.0k 0.6×	383 0.3×	716 0.7×	430 0.4×	120 0.2×	93	2.4k

Countries citing papers authored by Wolfgang Hueber

Since Specialization

Citations

This map shows the geographic impact of Wolfgang Hueber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wolfgang Hueber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wolfgang Hueber more than expected).

Fields of papers citing papers by Wolfgang Hueber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wolfgang Hueber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wolfgang Hueber. The network helps show where Wolfgang Hueber may publish in the future.

Co-authorship network of co-authors of Wolfgang Hueber

This figure shows the co-authorship network connecting the top 25 collaborators of Wolfgang Hueber. A scholar is included among the top collaborators of Wolfgang Hueber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wolfgang Hueber. Wolfgang Hueber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dörner, Thomas, Simon Bowman, Robert I. Fox, et al.. (2024). Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52‐Week Results From a Randomized, Placebo‐Controlled, Phase 2b Dose‐Ranging Study. Arthritis & Rheumatology. 77(5). 560–570. 3 indexed citations

Abetz‐Webb, Linda, et al.. (2023). Development and testing of an alternative responder definition for EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI). RMD Open. 9(1). e002721–e002721. 1 indexed citations

Séror, Raphaèle, Gabriel Baron, Marine Camus, et al.. (2022). Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases. 81(7). 979–989. 42 indexed citations

Bookman, Arthur, et al.. (2022). Content Validity of Sjögren’s Syndrome Symptom Diary and Functional Assessment of Chronic Illness Therapy-Fatigue in Patients with Sjögren’s. Rheumatology and Therapy. 9(6). 1559–1574. 7 indexed citations

Bookman, Arthur, et al.. (2022). Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren’s. Rheumatology and Therapy. 9(6). 1499–1515. 3 indexed citations

Baraliakos, Xenofon, Babul Borah, Juergen Braun, et al.. (2015). Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Annals of the Rheumatic Diseases. 75(2). 408–412. 61 indexed citations

Burmester, Gerd R, Patrick Durez, Mark C. Genovese, et al.. (2015). Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Lara D. Veeken. 55(1). 49–55. 37 indexed citations

Hueber, Wolfgang, Bruce E. Sands, Steve Lewitzky, et al.. (2012). Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 61(12). 1693–1700. 1156 indexed citations breakdown →

Emery, P., Dominique Baeten, Joachim Sieper, et al.. (2012). EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS. Lara D. Veeken. 51. 21–21. 6 indexed citations

10.

Baraliakos, Xenofon, Jerry Braun, Didier Laurent, et al.. (2011). Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging. Data Archiving and Networked Services (DANS). 63(10). 12 indexed citations

11.

McInnes, Iain B., John D. Isaacs, Hendrik Schulze‐Koops, et al.. (2011). Anti-Interleukin 17A Monoclonal Antibody Secukinumab Reduces Signs and Symptoms of Psoriatic Arthritis in a 24-Week Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Data Archiving and Networked Services (DANS). 2 indexed citations

12.

Deane, Kevin D., Colin O’Donnell, Wolfgang Hueber, et al.. (2010). The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age‐dependent manner. Arthritis & Rheumatism. 62(11). 3161–3172. 188 indexed citations

13.

Ho, Peggy P., Lowen Y. Lee, Xiaoyan Zhao, et al.. (2009). Autoimmunity against Fibrinogen Mediates Inflammatory Arthritis in Mice. The Journal of Immunology. 184(1). 379–390. 51 indexed citations

14.

Hueber, Wolfgang, Beren H. Tomooka, Franak Batliwalla, et al.. (2009). Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Research & Therapy. 11(3). R76–R76. 86 indexed citations

15.

Skriner, Karl, Wolfgang Hueber, E Höfler, et al.. (2008). AUF1, the regulator of tumor necrosis factor α messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases. Arthritis & Rheumatism. 58(2). 511–520. 18 indexed citations

16.

Hueber, Wolfgang, Brian Kidd, Beren H. Tomooka, et al.. (2005). Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis & Rheumatism. 52(9). 2645–2655. 214 indexed citations

17.

Hueber, Wolfgang, Defu Zeng, Samuel Strober, & Paul J. Utz. (2004). Interferon‐α–inducible proteins are novel autoantigens in murine lupus. Arthritis & Rheumatism. 50(10). 3239–3249. 23 indexed citations

18.

Hueber, Wolfgang, et al.. (2004). Characterization of novel antigens recognized by serum autoantibodies from anti‐CD1 TCR‐transgenic lupus mice. European Journal of Immunology. 34(6). 1654–1662. 4 indexed citations

19.

Robinson, William H., Wolfgang Hueber, Brian B. Haab, et al.. (2002). Autoantigen microarrays for multiplex characterization of autoantibody responses. Nature Medicine. 8(3). 295–301. 529 indexed citations breakdown →

20.

Hueber, Wolfgang, W. Hassfeld, Josef S Smolen, & G Steiner. (2000). Reply. Lara D. Veeken. 39(2). 218–218. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact